Document:

EXHIBIT 10.5

                     PATENT AND TECHNOLOGY LICENSE AGREEMENT

<PAGE>

EXHIBIT 10.5

                     PATENT AND TECHNOLOGY LICENSE AGREEMENT

         This twenty-six (26) page AGREEMENT ("AGREEMENT") is made on this 17th

day of February, 2005, by and between THE BOARD OF REGENTS ("BOARD") of THE

UNIVERSITY OF TEXAS SYSTEM ("SYSTEM"), an agency of the State of Texas, whose

address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY

OF TEXAS M. D. ANDERSON CANCER CENTER ("UTMDACC"), a component institution of

SYSTEM, and XPENTION, a Colorado corporation having a principal place of

business located at 10965 Elizabeth Drive, Conifer, Colorado 80433 ("LICENSEE").

                                TABLE OF CONTENTS

RECITALS                                                               Page 2

I. EFFECTIVE DATE                                                      Page 2

II. DEFINITIONS                                                        Page 2

III. LICENSE                                                           Page 5

IV. CONSIDERATION, PAYMENTS AND REPORTS                                Page 6

V. SPONSORED RESEARCH                                                  Page 10

VI. PATENTS AND INVENTIONS                                             Page 11

VII. INFRINGEMENT BY THIRD PARTIES                                     Page 11

VIII. PATENT MARKING                                                   Page 12

IX. INDEMNIFICATION AND INSURANCE                                      Page 13

X. USE OF BOARD AND UTMDACC'S NAME                                     Page 15

XI. CONFIDENTIAL INFORMATION AND PUBLICATION                           Page 15

XII. ASSIGNMENT                                                        Page 17

XIII. TERM AND TERMINATION                                             Page 17

XIV. WARRANTY: SUPERIOR-RIGHTS                                         Page 21

XV. GENERAL                                                            Page 22

SIGNATURES                                                             Page 25

                                       1
<PAGE>

                                    RECITALS

A.       BOARD owns certain PATENT RIGHTS and TECHNOLOGY RIGHTS related to

         LICENSED SUBJECT MATTER developed at UTMDACC.

B.       BOARD, through UTMDACC, desires to have the LICENSED SUBJECT CT MATTER

         developed in the LICENSED FIELD and used for the benefit of LICENSEE,

         BOARD, SYSTEM, UTMDACC, the inventor(s), and the public as outlined in

         BOARD's Intellectual Property Policy.

C.       LICENSEE wishes to obtain a license from BOARD to practice LICENSED

         SUBJECT MATTER.

         NOW, THEREFORE, in consideration of the mutual covenants and promises

herein contained, the parties agree as follows:

                                I. EFFECTIVE DATE

1.1      This AGREEMENT is effective as of the date written above ("EFFECTIVE
         DATE").

                                 II. DEFINITIONS

         As used in this AGREEMENT, the following terms have the meanings indi-

         cated:

2.1      AFFILIATE means any business entity more than fifty percent (50%) owned

         by LICENSEE, any business entity which owns more than fifty percent

         (50%) of LICENSEE, or any business entity that is more than fifty per-

         cent (50%) owned by a business entity that owns more than fifty percent

         (50%) of LICENSEE.

2.2      LICENSED FIELD means all fields of use.

2.3      LICENSED PRODUCTS means any product or service sold by LICENSED

         comprising LICENSED SUBJECT MATTER pursuant to this AGREEMENT LICENSED

                                       2
<PAGE>

         PRODUCTS shall include, byway of clarification, and not byway of

         limitation, services such as the diagnostic testing of biological

         samples (which testing uses or incorporates any LICENSED SUBJECT

         MATTER) and interpretation of such tests.

2.4      LICENSED SUBJECT MATTER means inventions and discoveries covered by

         PATENT RIGHTS or TECHNOLOGY RIGHTS within LICENSED FIELD.

2.5      LICENSED TERRITORY means worldwide.

2.6      NET SALES means the gross revenues received by LICENSEE or a STRATEGIC

         PARTNER from or as a result of a SALE, less sales discounts actually

         granted, sales and/or use taxes actually paid, import and/or export

         duties actually paid, outbound transportation actually prepaid or

         allowed, and amounts actually allowed or credited due to returns (not

         exceeding the original billing or invoice amount), all is recorded by

         LICENSEE in LICENSEE's official books and records in accordance with

         generally accepted accounting practices and consistent with LICENSEE's

         published financial statements and/or regulatory filings with the

         United States Securities and Exchange Commission. NET SALES shall not

         include revenues received by LICENSEE from a STRATEGIC PARTNER for

         LICENSED PRODUCTS provided by LICENSEE to the STRATEGIC PARTNER for

         resale by the STRATEGIC PARTNER.

2.7      PATENT RIGHTS means BOARD's rights in the information or discoveries

         claimed in the patents listed on Exhibit I and any reissues,

         reexaminations or extensions as thereof.

2.8      SALE or SOLD means the transfer or disposition of a LICENSED PRODUCT

         for value to a party other than LICENSEE or AFFILIATE.

                                       3
<PAGE>

2.9      STRATEGIC ALLIANCE means a written agreement between LICENSEE a third

         party ("STRATEGIC PARTNER") in which the STRATEGIC PARTNER agrees to

         manufacture, market and/or sell LICENSED PRODUCTS for LICENSEE. To

         qualify as a STRATEGIC ALLIANCE for veterinary diagnostic use, the

         agreement must guarantee annual NET SALES of LICENSED PRODUCTS for

         veterinary diagnostic use by LICENSEE or the STRATEGIC PARTNER in

         excess of US$1 00,000 per year. To qualify as a STRATEGIC ALLIANCE for

         human diagnostic use, the agreement must guarantee annual NET SALES of

         LICENSED PRODUCTS for human diagnostic tic use by LICENSEE or the

         STRATEGIC PARTNER in excess of US$250,000 per year. Any STRATEGIC

         PARTNER must agree in writing to be bound by all the terms and

         provisions of this AGREEMENT to the same extent as if it were the

         LICENSEE. Other than a sublicense agreement as described in Sections

         3.3 and 3.4. LICENSEE may not enter into a STRATEGIC ALLIANCE with a

         third party without the prior written approval of the terms of the

         STRATEGIC ALLIANCE by UTMDACC, which approval

         will not be unreasonably withhold, LICENSEE shall furnish UTMDACC a

         copy of any STRATEGIC ALLIANCE within thirty (30.) days after execution

         by all parties.

2.10     TECHNOLOGY RIGHTS means BOARD's rights in any technical information,

         know-how processes, procedures, compositions, devices, methods,

         formulae, protocols, techniques, software, designs, drawings or data

         created by the inventor(s) listed in Exhibit I at UTMDACC before the

         EFFECTIVE DATE, which are not claimed aimed in PATENT RIGHTS but that

         are necessary for practicing PATENT RIGHTS.

                                       4
<PAGE>

                                  III. LICENSE

3.1      BOARD, through UTMDACC, hereby grants to LICENSEE a royalty-bearing,

         exclusive license under LICENSED SUBJECT MATTER to manufacture, have

         manufactured, use, import, offer to sell and/or sell LICENSED PRODUCTS

         within LICENSED TERRITORY for use within LICENSED FIELD, This grant is

         subject to Sections 14.2 and 14.3 hereinbelow, the payment by LICENSEE

         to UTMDACC of all consideration as provided herein, the timely payment

         of all amounts due under any related sponsored research agreement

         between UTMDACC and LICENSEE in effect during this AGREEMENT, and is

         further subject to the following rights retained by BOARD and UTMDACC

         to:

         (a)      Publish the general scientific findings from research related

                  LICENSED SUBJECT MATTER, subject to the terms of Article XI-

                  Confidential formation and Publication; and

         (b)      Use LICENSED SUBJECT MATTER for research, teaching, patient

                  care, and other educationally-related purposes.

3.2      LICENSEE may extend the license granted herein to any AFFILIATE

         provided that the AFFILIATE consents in writing to be bound by this

         AGREEMENT to the same extent as LICENSEE. LICENSEE agrees to deliver

         such contract to UTMDACC within thirty (30) calendar days following

         execution thereof.

3.3      LICENSEE may grant sublicenses under LICENSED SUBJECT MAT ER consistent

         with the terms of this AGREEMENT provided that LICENSEE is responsible

         for its sublicensees relevant to this AGREEMENT, and for diligently

         collecting all amounts due

                                       5
<PAGE>

         LICENSEE from sublicensees. If a sublicensee pursuant hereto becomes

         bankrupt, insolvent or is placed in the hands of a receiver or trustee.

         LICENSE to the extent allowed under applicable law and in a timely

         manner, agrees to use its best reasonable efforts to collect all

         consideration owed to LICENSEE and to have the sublicense agreement

         confirmed or rejected by a court of proper jurisdiction.

3.4      LICENSEE must deliver to UTMDACC a true and correct copy of each

         sublicense granted by LICENSEE, and any modification or termination

         thereof, within thirty (30) calendar days after execution,

         modification, or termination.

3.5      If this AGREEMENT is terminated pursuant to Article XIII-Term and

         Termination, BOARD and UTMDACC agree to accept as successors to LICENSE

         existing sublicensees in good standing at the date of termination

         provided at each such, sublicensee consents in writing to be bound by

         all of the terms and conditions of this AGREEMENT.

                     IV. CONSIDERATION, PAYMENTS AND REPORTS

4.1      In consideration of rights granted by BOARD to LICENSEE under this

         AGREEMENT, LICENSEE agrees to pay UTMDACC the following:

         (a)      All out-of-pocket expenses incurred by UTMDACC after the

                  EFFECTIVE DATE in filing, prosecuting, enforcing and maintain-

                  ing PATENT RIGHTS and all such future expenses incurred by

                  UTMDACC, for so long as, and in such countries as this AGREE-

                  MENT remains in effect. In the event any expenses are due,

                  UTMDACC will invoice LICENSEE within thirty (30) calendar days

                  after the EFFECTIVE DATE for any expenses incurred as of that

                  time. UTMDACC will invoice LICENSEE an a quarterly basis there

                  -after.

                                       6
<PAGE>

                  The invoiced amounts will be due and payable by LICENSEE

                  within thirty (30) calendar days of invoice; and

         (b)      A nonrefundable license documentation fee in the amount of US$

                  50,000.00. This fee will not reduce the amount of any other

                  payment provided for in this ARTICLE IV, and is due and

                  payable within thirty (30) calendar days after the AGREEMENT

                  has been fully executed by all parties and LICENSEE has

                  received an invoice for the amount from UTMDACC; and

         (c)      A running royalty equal to five and one-half percent (5.5%) of

                  NET SALES; and

         (d)      The following one time milestone payments due within thirty

                  (30) days after occurrence of the following events:

                  (i)      US$50,000.00 upon the first SALE of a LICENSED

                           PRODUCT for veterinary diagnostic use; and

                  (ii)     US$50,000,00 upon the earlier to occur of the follow-

                           ing events:  (1) the filing of a Biological License

                           Application for a human diagnostic use in the U.S. or

                           an equivalent foreign filing in any other national

                           political jurisdiction for a LICENSED PRODUCT; or (2)

                           the first SALE of a LICENSED PRODUCT for human diagno

                           -stic use; and

         (e)      Fifty percent (50%) of all consideration, other than research

                  development money, received by LICENSEE from either (i) any

                  sublicensee pursuant to Sections 3.3 and 3.4 hereinabove that

                  is not also a STRATEGIC PARTNER, or (ii) any assignee pursuant

                  to Section 12.1 hereinbelow (in consideration for UTMDACC

                  allowing the assignment), including but not limited to,

                                       7
<PAGE>

                  royalties, up-front payments, marketing, distribution,

                  franchise, option, license, or documentation fees, bonus and

                  milestone payments and equity securities.

4.2      Unless otherwise provided, all such payments are payable within thirty

         (30) calendar days after March 31, June 30, September 30, and December

         31 of each year during the term of this AGREEMENT, at which time

         LICENSEE will also deliver to UTMDACC a true and accurate report,

         giving such particulars of the business conducted by LICENSEE and its

         sublicensees and STRATEGIC PARTNERS, if any exist, during the preceding

         three calendar months under this AGREEMENT as necessary for UTMDACC to

         account for LICENSEE's payments hereunder. This report will include

         pertinent data, including, but not limited to:

         (a)      the accounting methodologies used to account for and calculate

                  the items included in the report and any differences in such

                  accounting methodologies used by LICENSEE since the previous

                  report; and

         (b)      a list of LICENSED PRODUCTS produced for the three (3) preced-

                  ing calendar months categorized by the technology it relates

                  to under PATENT RIGHTS; and

         (c)      the total quantities of LICENSED PRODUCTS produced by the cate

                  -gory listed in Section 4.2(b); and

         (d)      the total SALES by the category listed in. Section 4.2(b); and

         (e)      the calculation of NET SALES by the category listed in Section

                  4.2(b); and

         (f)      the royalties so computed and due LJTMDACC by the category

                  listed in Section 4.2(b) and/or minimum royalties; and

                                       8
<PAGE>

         (g)      all consideration received from each STRATEGIC PARTNER, sub-

                  licensee or assignee and payments due UTMDACC; and

         (h)      all other amounts due UTMDACC herein.

         Simultaneously with the delivery of each such report, LICENSEE agrees

         to pay UTMDACC the amount due, if any, for the period or such report.

         These reports are required even if no payments are due.

4.3      During the term of this AGREEMENT and for one (1) year thereafter,

         LICENSEE agrees to keep complete and accurate records of its STRATEGIC

         PARTNER's and its sublicensees' SALES in sufficient detail to enable

         the royalties and other payments due hereunder to be determined.

         LICENSEE agrees to permit UTMDACC or its representatives, at UTMDACC's

         expense, to periodically examine LICENSEE's books, ledgers, and records

         during regular business hours for the purpose of and the extent

         necessary to verify any report required under this AGREEMENT. If any

         amounts due UTMDACC are determined to have been underpaid in an amount

         equal or greater than five percent (5%) of the total amount due during

         the period so examined, then LICENSEE will pay the cost of the

         examination plus accrued interest at the highest allowable rate.

4.4      Within thirty (30) calendar days following each anniversary of the

         EFFECTIVE DATE, LICENSEE will deliver to UTMDACC a written progress

         report as to LICENSEE's (and, any sublicensee's or STRATEGIC PARTNER's)

                                       9
<PAGE>

         efforts and accomplishments during the preceding year in diligently

         commercializing LICENSED SUBJECT in the LICENSED TERRITORY and

         LICENSEE's (and sublicensees' or STRATEGIC PARTNER's) commercialization

         plans for the upcoming year.

4.5      All amounts payable hereunder by LICENSEE will be paid in United States

         funds without deductions for taxes, assessments, fees, or charges of

         any kind. Checks are to be made payable to The University of Texas

         M. D. Anderson Cancer Center, and sent by United States mail to Box

         297402, Houston, Texas 77297, Attention: Manager, Sponsored Programs or

         by wire transfer to:

         BANK ONE TEXAS
         910 TRAVIS
         HOUSTON, TEXAS 77002
         SWIFT: BONEUS44HOU

         ABA ROUTING NO: 111000614
         ACCOUNT NAME: UNIV. OF TEXAS M.D. ANDERSON CANCER CENTER
         ACCOUNT NO: 1586838979
         REFERENCE:       include title and EFFECTIVE DATE of AGREEMENT and type
         of payment (e.g,, license documentation fee, milestone payment, royalty
         [including applicable patent/application identified by MDA reference
         number and patent number or application serial number], or maintenance
         fee, etc.).

4.6      No payments due or royalty rates owed under this AGREEMENT will be

         reduced as the result of co-ownership of LICENSED SUBJECT MATTER by

         BOARD and another party, including, but not limited to, LICENSEE.

                              V. SPONSORED RESEARCH

5.1      If LICENSEE desires to sponsor research for or related to the LICENSED

         SUBJECT MATTER, and particularly where LICENSEE receives payments for

         sponsor research pursuant to a sublicense under this AGREEMENT,

         LICENSEE (a) will notify UTMDACC in writing of all opportunities to

         conduct this sponsored research (including clinical trials, if

                                       10
<PAGE>

         applicable), (b) solicit research and/or clinical proposals from

         UTMDACC for this purpose, and (c) will give good faith consideration to

         funding the proposals at UTMDACC.

                           VI. PATENTS AND INVENTIONS

6.1      If after consultation with LICENSEE both parties agree that a new

         patent application should be filed for LICENSED SUBJECT MATTER, UTMDACC

         will prepare and file appropriate patent applications, and LICENSEE

         will pay the cost of searching, preparing, filing, prosecuting and

         maintaining same. If LICENSEE notifies UTMDACC that at it does not

         intend to pay the cost of an application, or if LICENSEE does not

         respond make an effort to agree with UTMDACC on the disposition of

         rights of the subject invention, then UTMDACC may file such application

         at its own expense and LICENSEE's rights to such invention under this

         AGREEMENT shall terminate in their entirety, UTMDACC will provide

         LICENSEE with a copy of the application for which LICENSE has paid the

         cost of filing, as well as copies of any documents received or filed

         during prosecution thereof. The parties agree that they share a common

         legal interest to get valid enforceable patents and that LICENSEE will

         keep all privileged info it received pursuant to this Section confiden-

         tial.

                       VII. INFRINGEMENT BY THIRD PARTIES

7.1      LICENSEE, at its expense, must enforce any patent exclusively licenced

         hereunder against infringement by third parties and is entitled to

         retain recovery from such enforcement, After reimbursement of

         LICENSEE's reasonable legal cost an expenses related to such recovery,

         LICENSEE agrees to pay UTMDACC either: (a) the royalty detailed in

         Section 4.1 (d) for any monetary recovery that is for sales of LICENSED

                                       11
<PAGE>

         PRODUCTS lost due to the infringement and related punitive damages; or

         (b) fifty percent (50%) of reasonable royalties awarded and related

         punitive damages in any recovery in which the award is for reasonable

         royalties. LICENSE mmust notify UTMDACC in writing of any potential

         infringement within thirty (30) calendar days of knowledge thereof If

         LICENSEE does not file suit against a substantial infringer within six

         (6) months of knowledge thereof, then BOARD or LJTMDACC may, its sole

         discretion, enforce any patent licensed hereunder on behalf of itself

         rand LICENSEE, with UTMDACC retaining all recoveries from such

         enforcement, and/or reduced the license granted hereunder to

         non-exclusive.

7.2      In any suit or dispute involving an infringer, the parties agree to

         cooperate fully with each other. At the request and expense of the

         party bringing suit, the other party will permit access during regular

         business hours, to all relevant personnel, records, papers,

         information, samples, specimens, and the like in its possession.

                              VIII. PATENT MARKING

8.1      LICENSEE agrees that all packaging containing individual LICENSED

         PRODUCT(S), documentation therefor, and when possible for actual

         LICENSED PRODUCT(S) sold by LICENSEE, AFFILIATES, STRATEGIC PARTNERS

         and/or a sublicensees of LICENSEE will be permanently and legibly

         marked with the number of an applicable patent(s) licensed hereunder in

         accordance with each country's patent law, including Title 35, United

         States Code.

                                       12

<PAGE>

                        IX. INDEMNIFICATION AND INSURANCE

9.1      LICENSEE agrees to hold harmless and indemnify BOARD, SYSTEM, UTMDACC,

         its Regents, officers, employees, students and agents from and against

         any claims, demands, or causes of action whatsoever, costs of suit and

         reasonable attorney's fees, including without limitation, those costs

         arising on account of any injury or death of persons or damage to

         property caused by, or arising out of, or resulting from, the exercise

         or practice of the rights granted hereunder by LICENSEE, its officers,

         its AFFILIATES or their officers, employees, agents or representatives.

9.2      In no event shall BOARD, SYSTEM or UTMDACC be liable for any in

         indirect, special, consequential or punitive damages (including, with-

         out limitation, damages or loss of profits or expected savings or other

         economic losses, or for injury to persons property) arising out of, or

         in connection with, this AGREEMENT or its subject matter, regardless

         of whether BOARD, SYSTEM or UTMDACC knows or should know of the possi-

         bility of such damages. The total aggregate liability of BOARD, SYSTEM

         an UTMDACC for all damages of any kind relating to this AGREEMENT or

         its subject att shall not exceed the amounts paid by LICENSEE to BOARD

         or UTMDACC under this AGREEMENT during the one (1) year period preced-

         ing the date of the event that gave rise to the liability. The fore-

         going exclusions and limitations shall apply to all claims and actions

         of any kind, whether based on contract, tort (including, but not limit-

         ed to, negligence), or any other grounds.

9.3      Beginning at the time when any LICENSED SUBJECT MATTER is being distrib

         -uted or sold (including for the purpose of obtaining regulatory

         approvals) by LICENSEE or by a

                                       13
<PAGE>

         sublicensee or STRATEGIC PARTNER, LICENSEE shall, at its sole cost and

         expense, procure and maintain commercial general liability insurance in

         amounts not less than US$2,000,000 per incident and US$2,000,000 annual

         aggregate, and LICENSEE shall use reasonable efforts to have the BOARD,

         SYSTEM, UTMDACC, its Regents, officers, employees, students and agents

         named as additional insureds. Such commercial general liability

         insurance shall provide: (i) product liability coverage; (ii) broad

         form contractual liability coverage for LICENSEE's indemnification

         under this AGREEMENT; and. (iii) coverage for litigation costs. The

         minimum amounts of insurance coverage age required herein shall not be

         construed to create a limit of LICENSEE's liability with respect to its

         indemnification under this AGREEMENT.

9.4      LICENSEE shall provide UTMDACC with written evidence of such insurance

         within thirty (30) days of its procurement, Additionally, LICENSEE

         shall provide UTMDACC with written notice of at least fifteen (15) days

         prior to the cancellation, non-renewable or material change in such

         insurance.

9.5      LICENSEE shall maintain such commercial general, liability insurance

         beyond the expiration or termination of this AGREEMENT during: (i) the

         period that any LICENSED SUBJECT MATTER developed pursuant to this

         AGREEMENT is being commercially distributed or sold by LICENSEE or by a

         sublicensee, STRATEGIC PARTNER or agent of LICENSEE; and (ii) the five

         (5) year period immediately after such period.

                                       14
<PAGE>

                       X. USE OF BOARD AND UTMDACC'S NAME

10.1     LICENSEE will not use the name of (or the name of any employee of

         UTMDACC, SYSTEM or BOARD in any advertising, promotional or sales

         literature, on its Web site, or for the purpose of raising capital

         without the advance express written consent of BOARD secured through:

         M. D. Anderson Services Corporation
         7505 S. Main, Suite 500, Unit 0525
         Houston, TX 77030
         ATTENTION: Natalie Wright
         Email: nwright@mdanderson.org

         Notwithstanding the above, LICENSEE may use the name of (or name of

         employee of) UTMDACC, SYSTEM or BOARD in routine business

         correspondence, or a needed in appropriate regulatory submissions

         without express written consent.

                  XI. CONFIDENTIAL INFORMATION AND PUBLICATION

11.1     UTMDACC and LICENSEE each agree that all information contained in

         documents marked "confidential" and forwarded to one by the other (i)

         are to received in strict confidence, (ii) are to be used only for the

         purposes of this AGREEMENT, and (iii) will not be disclosed by the

         recipient party (except as required by law or court order), its agents

         or employees without the prior written consent of the other party,

         except to the extent that the recipient party can establish by

         competent written proof that such information:

         (a)      was in the public domain at the time of disclosure; or

         (b)      later became part of the public domain through no act or

                  omission of the recipient party, its employees, agents,

                  successors or assigns; or

                                       15
<PAGE>

         (c)      was lawfully disclosed to the recipient party by a third party

                  having the right to disclose it, or

         (d)      was already known by the recipient party at the time of dis-

                  closure; or

         (e)      was independently developed by the recipient without use of

                  the other party's confidential information; or

         (f)      is required by law or regulation to he disclosed.

11.2     Each party's obligation of confidence hereunder will be fulfilled by

         using least the same degree of care with the other party's confidential

         information as it uses to protect its own confidential information, bat

         always at least a reasonable degree of are. This obligation will exist

         while this AGREEMENT is in force and for a period of three (3) years

         thereafter.

11.3     UTMDACC reserves the right to publish the general scientific findings

         from research related to LICENSED SUBJECT MATTER, with due regard to

         the protection of LICENSEE's confidential information. UTMDACC will

         submit the manuscript of any proposed publication to LICENSEE at least

         thirty (30) calendar days before publication, and LICENSEE shall have

         the right to review and comment upon the publication in order to

         protect LICENSEE's confidential information. Upon LICENSEE's request,

         publication may be delayed up to sixty (60) additional calendar days to

         enable LICENSEE to secure adequate intellectual property protection of

         LICENSEE's confidential information that would otherwise be affected by

         the publication.

                                       16
<PAGE>

                                 XII. ASSIGNMENT

12.1     Except in connection with the sale of all or LICENSEE's assets to a

         third party, this AGREEMENT may not be assigned by LICENSEE without the

         prior written consent of UTMDACC, which will not be unreasonably

         withheld.

                           XIII. TERM AND TERMINATION

13.1.    Subject to Sections 13.5 and 13.6 hereinbelow, the term of this AGREE-

         MENT is from the EFFECTIVE DATE to the full end of the term or terms

         for which PATENT RIGHTS have not expired, or if only TECHNOLOGY RIGHTS

         are licensed and no PATENT RIGHTS are applicable, for a term of fifteen

         (15) years.

13.2     Any time after one (1) year from the EFFECTIVE DATE, BOARD or UTMDACC

         have the right to terminate this license in any national political

         jurisdiction within the LICENSED TERRITORY if LICENSEE, within ninety

         (90) calendar days after receiving written notice from UTMDACC of the

         intended termination, fails to provide written evidence satisfactory to

         UTMDACC that LICENSEE or its sublicensee(s) or STRATEGIC PARTNERS has

         commercialized or is actively and effectively attempting to

         commercialize a licensed invention in such jurisdiction(s). The

         following definitions apply to Section 13.2: (a) "commercialize" means

         having SALES in such jurisdiction; (b) "active attempts to

         commercialize" means having an effective, ongoing and active research,

         development, manufacturing, marketing or sales program as appropriate,

         directed toward obtaining regulatory approval, and/or production and/or

                                       17
<PAGE>

         SALES in any jurisdiction, and has provided plans acceptable to

         UTMDACC, in its sole discretion, to commercialize licensed inventions

         in the jurisdiction(s) that UTMDACC intends to terminate.

13.3     Any time after one (1) year from the EFFECTIVE DATE, BOARD or UTMCACC

         have the Right to terminate the AGREEMENT in any national political

         jurisdiction within the LICENSED TERRITORY if LICENSEE fails to either:

         (1) make a SALE of a LICENSED PRODUCT for veterinary diagnostic use; or

         (2) enter into a STRATEGIC ALLIANCE for veterinary diagnostic use. Not-

         withstanding the foregoing, LICENSEE may extend the one (1) year period

         provided in this Section 13.3 for an additional six (6) months if

         LICENSEE notifies UTMDACC of its desire to extend before expiration of

         the one (1) year period and pays a US$25,000.00 extension fee to

         UTMDACC within thirty (30) days thereafter.

13.4     Any time after two (2) years from the EFFECTIVE DATE, BOARD or UTMCACC

         shall have the right to terminate the AGREEMENT in any national

         political jurisdiction within the LICENSED TERRITORY if LICENSEE fails

         to either: (1) obtain regulatory approval of a Biological License

         Application for human diagnostic use in the U.S. or an equivalent

         foreign filing in any other national political jurisdiction for a

         LICENSED PRODUCT; (2) make a SALE of a LICENSED PRODUCT for human

         diagnostic use; or (3) enter into a STRATEGIC ALLIANCE for human

         diagnostic use. Notwithstanding the foregoing, LICENSEE may extend the

         two (2) year period provided in this Section 13.4 for an additional six

         (6) months if LICENSEE notifies UTMDACC of it desire to extend before

         expiration of the two (2) year period and pays a US$25,000.00 extension

         fee to UTMDACC within thirty (30) days thereafter.

                                       18
<PAGE>

13.5     Subject to any rights herein which survive termination, this AGREEMENT

         earlier terminate in its entirety:

         (a)      automatically, if LICENSEE becomes bankrupt or insolvent

                  and/or if the business of LICENSEE shall be placed in the

                  hands of a receiver, assignee, or trustee, whether by volun-

                  tary act of LICENSEE or otherwise; or

         (b)      upon thirty (30) calendar days written notice from UTMDACC, if

                  LICENSEE breaches or defaults on the payment or report

                  obligations of ARTICLE IV, or use of name obligations of

                  ARTICLE X, unless, before the end of the such thirty (30)-

                  calendar day notice period, LICENSEE has cured the default or

                  breach to UTMDACC's satisfaction, and so notifies UTMDACC,

                  stating the manner of the cure, or

         (c)      upon ninety (90) calendar days written notice from UTMDACC if

                  LICENSEE breaches or defaults on any other obligation under

                  this AGREEMENT, unless, before the end of the such ninety (90)

                  calendar-day notice period, LICENSEE has cured the default or

                  breach to UTMDACC's satisfaction and so notifies UTMDACC,

                  stating the manner of the cure; or

         (d)      at any time by mutual written agreement between LICENSEE and

                  UTMDACC upon one hundred eighty (180) calendar days written

                  notice to all parties and subject to any terms herein which

                  survive termination; or

         (e)      if Section 13.2 is invoked; or

                                       19
<PAGE>

         (f)      if LICENSEE has defaulted or been late on its payment

                  obligations pursuant to the terms of this AGREEMENT on any two

                  (2) occasions in a twelve (12) month period.

13.6     Upon termination of this AGREEMENT:

         (a)      nothing herein will be construed to release either party of

                  any obligation maturing prior to the effective date of the

                  termination; and

         (b)      LICENSEE covenants and agrees to be bound by the provisions of

                  Articles IX (Indemnification and Insurance), X (Use of Board

                  and UTMDACC's Name) and XI (Confidential Information and

                  Publication) of this AGREEMENT; and

         (c)      LICENSEE may, after the effective date of the termination,

                  sell all LICENSED PRODUCTS and parts therefor that it has on

                  hand at the date of termination, if LICENSEE pays the earned

                  royalty thereon and any other amounts due pursuant to Article

                  IV of this AGREEMENT: and

         (d)      Subject to Section 13.6(c), LICENSEE agrees to cease and

                  desist any use and all SALE of the LICENSED SUBJECT MATTER and

                  LICENSE PRODUCTS upon termination of this AGREEMENT; and

         (e)      LICENSEE grants to BOARD and UTMDACC a nonexclusive royalty

                  bearing license with the right to sublicense others with

                  respect to improvement made by LICENSEE (including improve-

                  ments licensed by LICENSEE from third parties) in the LICENSED

                                       20
<PAGE>

                  SUBJECT MATTER. LICENSEE and UTMDACC agree to negotiate in

                  good faith the royalty rate for the nonexclusive license.

                  BOARD's and UTMDACC's right to sublicense others hereunder is

                  solely for the purpose of permitting others to develop and

                  commercialize the entire technology package.

                         XIV. WARRANTY: SUPERIOR-RIGHTS

14.1     Except for the rights, if any, of the Government of the United States

         of America as set forth below, BOARD represents and warrants its belief

         that (a) it is the owner of the entire right, title, and interest in

         and to LICENSED SUBJECT MATTER, (b) it has the sole right to grant

         licenses thereunder, and (c) it has not knowingly granted to licenses

         thereunder to any other entity that would restrict rights granted

         hereunder except as stated herein.

14.2     LICENSEE understands that the LICENSED SUBJECT MATTER may have been

         developed under a funding agreement with the Government of the United

         States of America and, if so, that the Government may have certain

         rights relative thereto. This AGREEMENT is explicitly made subject to

         the Government's rights under any such agreement and any applicable law

         or regulation, including P.L. 96-517 as amended ended by P.L. 98-620.

         To the extent that there is a conflict between any such agreement,

         applicable law or regulation and this AGREEMENT, the terms of such

         Government agreement, applicable law or regulation shall prevail.

14.3     LICENSEE understands and agrees that BOARD and UTMDACC, by this

         AGREEMENT, make no representation as to the operability or fitness for

         any use, safety, efficacy, approvability by regulatory authorities,

         time and cost of development, patentability, and/or breadth of the

                                       21
<PAGE>

         LICENSED SUBJECT MATTER. BOARD and UTMDACC, by this AGREEMENT, also

         make no representation as to whether any patent covered by PATENT

         RIGHTS is valid or as to whether there are any p -tents now held, or

         which will be held, by others or by BOARD or UTMDACC in the LICENSED

         FIELD, nor does BOARD and UTMDACC make any representation that the

         inventions contained in PATENT RIGHTS do not infringe any other patents

         now held or that will be held by others or by BOARD.

14.4     LICENSEE, by execution hereof, acknowledges. covenants and agrees that

         LICENSEE has not been induced in any way by BOARD, SYSTEM, UTMDACC or

         employees thereof to enter into this AGREEMENT, and further warrants

         and represents that (a) LICENSEE has conducted sufficient due diligence

         with respect to all it a and issues pertaining to this AGREEMENT; and

         (b) LICENSEE has adequate knowledge and expertise, or has used

         knowledgeable and expert consultants, to adequately conduct such due

         diligence, and agrees to accept all risks inherent herein.

                                   XV. GENERAL

15.1     This AGREEMENT constitutes the entire and, only agreement between the

         parties for LICENSED SUBJECT MATTER and all other prior negotiations,

         representations, agreements and understandings are superseded hereby.

         No agreements altering or representation supplementing the terms hereof

         will be made except by a written document signed by both parties.

15.2     Any notice required by this AGREEMENT must be given by prepaid, docu-

         ment certified mail, return receipt requested, and addressed in the

         case of UTMDACC to:

         The University of Texas M. D. Anderson Cancer Center
         Office of Technology Commercialization
         7515 S. Main, Suite 490, Unit 0510
         Houston, Texas 77030
         ATTENTION: William J. Doty

                                       22
<PAGE>

         with copy to BOARD:

         BOARD OF REGENTS
         The University of Texas System
         201 West Seventh Street
         Austin, Texas 78701
         ATTENTION: Office of General Counsel

         or in the case of LICENSEE to:

         XPENTION
         10965 Elizabeth Drive
         Conifer, Colorado 80433
         ATTENTION: David Kittrell, President and CEO

         or other addresses as may be given from time to time under the terms of

         is notice provision.

15.3     LICENSEE must comply with all applicable federal, state and local laws

         and regulations in connection with its activities pursuant to this

         AGREEMENT.

15.4     This AGREEMENT will be construed and enforced in accordance with the

         laws of the United States of America and of the State of Texas, without

         regard to its conflict of law provisions. The Texas State Courts of

         Harris County, Texas (or, if there is exclusive federal jurisdiction,

         the United States District Court for the Southern District of Texas)

         shall have exclusive jurisdiction and venue over any dispute arising

         out of this AGREEMENT, and LICENSEE consents to the jurisdiction of

         such courts; however, nothing herein shall be deemed as a waiver by

         BOARD, SYSTEM or UTMDACC or its sovereign immunity.

                                       23
<PAGE>

15.5     Any dispute or controversy arising out of or relating to this

         AGREEMENT, its construction or its actual or alleged breach will he

         decided by mediation. It the mediation does not result in a resolution

         of such dispute or Controversy, it will be finally decide by an

         appropriate method of alternate dispute resolution, including without

         limitation, arbitration, conducted in the city of Houston, Harris

         County, Texas, in accordance with the applicable, then-current

         procedures of the American. Arbitration Association. The arbitration

         panel will include members knowledgeable in the evaluation of the

         LICENSED SUBJECT MATTER. Judgment upon the award rendered may be

         entered in the highest court or forum having jurisdiction, state or

         federal. The provisions of this Section 15.5 will not apply to

         decisions on the validity of patent claims or to any dispute or

         controversy as to which any treaty or law prohibits such arbitration.

         The decision of the arbitration must be sanctioned by a court of law

         having jurisdiction to be binding upon and enforceable by the parties.

15.6     Failure of BOARD or UTMDACC to enforce a right under this AGREEMENT

         will not act as a waiver of right or the ability to later assert that

         right relative to the particular situation involved.

15.7     Headings included herein are for convenience only and will not be used

         to construe this AGREEMENT.

15.8     If any part of this AGREEMENT is for any reason found to be

         unenforceable, all other parts nevertheless will remain enforceable.

                                       24
<PAGE>

         IN WITNESS WHEREOF, the parties hereto have caused their duly

authorized representatives to execute this AGREEMENT.

BOARD OF REGENTS OF THE
UNIVERSITY OF TEXAS

By: /s/ John Mendelsohn                        XPENTION
    ---------------------------------
         John Mendelsohn
         President                             By: /s/ David M. Kittrell
         The University of Texas                   -----------------------------
         M. D. Anderson Cancer Center                David M. Kittrell
                                                     President
Date: 2/17/05
                                               Date: 2/1/05
THE UNIVERSITY OF TEXAS
M. D. ANDERSON CANCER CENTER

By: /s/ Leon Leach
    ---------------------------------------------------
         Leon Leach
         Executive Vice President
         The University of Texas
         M. D. Anderson Cancer Center
Date: 2/15/05

Approved as to Content:

By: /s/ William J. Doty
    -------------------------------------------
         William J. Doty
         Managing Director, Technology
         Commercialization
         M. D. Anderson Cancer Center

Date: 2/8/05

                                       25
<PAGE>

                                    EXHIBIT I

MDA89-015, which consists of the following three patents:

"Tumor Marker Protein and Antibodies Thereto for Cancer Risk Assessment or Diag-
nosis," U.S. Patent No. 5,310,653, Issued May 10, 1994, Inventors: Margaret
Hanausek-Walaszek; Thomas J. Slaga; Zbigniew Walaszek.

"Diagnostic and Premonitoring Uses of a 65 kDa Tumor-Associated Protein in Com-
panion and Domestic Animal Malignancy," U.S. Patent No. 5,411,868, Issued May 2,
1995; Inventors: Margaret Hanausek-Waluszek; Lezlee Coghlan.

"Tumor Marker Protein for Cancer Risk Assessment,: U.S, Patent No. 5,773,215,
Issued June 30, 1998, Inventors: Margaret Hanausek-Walaszek; Thomas J. Slap; and
Zbigniew Walaszek.

                                       26EXHIBIT 10.6

                     ABSTRACT ON P65 TESTS ON TUMOR MARKERS

<PAGE>

[Figure omitted]

Fig 1.  Anti-canine p65 antibody standard curve determination. Purified canine
p65 (40 ng/well 1000 ng/well) was bound to microtiter plate and blocked with
Tris-buffered saline containing bovine serum albumin (1% wt/vol). The plates
were probed with serial dilutions of preimmune and postimmune blood serum. Blood
sera were diluted up to 10000 x.

<PAGE>

[Figure omitted]

Fig. 2.  Binding of purified canine p65(1), rat p65 (2), b-amylase (3) and

alcohol dehydrogenase (4) by anti-canine p65 serum in indirect ELISA.

<PAGE>

[Figure omitted]

Fig. 2b. Binding of canine p65 and nonspecific protein apoferritin

<PAGE>

[Figure omitted]

Fig 3. Specificity of polyclonal antibody obtained against purified canine p65
analyzed by Western blot Purified rat and canine p65 (2 ug/lane) was separated
by SDS-PAGE and electrotransferred to nitrocellulose membrane prior to probing
with preimmune and postimmune blood serum.

<PAGE>

[Figure omitted]

Fig 4. Scatter diagram of p65 concentration in 32 normal subjects and 87 dogs
with lymphoma.

<PAGE>

Title

Lezlee Coghlan*, DVM., Margaret Hanausek^, Ph.D. , William Satterfield*, DVM.,

Department of Carcinogenesis^,  Science Park-Research Division, The University

of Texas M.D. Anderson Cancer Center1, Smithville, TX 78957, *Department of

Veterinary Resources, Science Park-Veterinary Resources Division, Bastrop, TX

Abstract

         Cancer is commonly encountered in pet animal practices and is one of

the leading causes of pet death. While the pet's prognosis is dependent upon

various factors including tumor type and stage at diagnosis, for the vast

majority of cancers, early detection and treatment are extremely important in

successful cancer therapy. Although various tumor markers have been shown to be

useful diagnostic and prognostic indicators in human oncology [1-3], their

application to companion animal medicine has barely been explore [4,5]. The

ideal tumor marker would be produced only by malignant cells, be detectable

early after the onset of tumor formation, and have levels that directly

correlate with tumor burden [3]. Our preliminary studies with a 65-kD

tumor-associated protein, hereafter referred to as p65, in spontaneous canine

lymphosarcoma cases and experimentally induced malignancies in rodent models

indicate that this tumor marker possesses these ideal characteristics and has

great potential utility in companion animal cancer medicine. We have developed a

test for veterinary application in the differential diagnosis of malignancy, in

assessing patient response to cancer therapy, and in monitoring clinical

remission to enable the prompt detection of cancer recurrence using double

sandwich ELISA with monoclonal and polyclonal antibodies to p65.

<PAGE>

Introduction

Lymphosarcoma is the most common hematopoietic malignancy of dogs, having an

annual incidence between 6-30 cases/100,000 dogs [6-9]. Diagnosis is best made

by biopsy, therefore, most veterinary clinics must use outside diagnostic

resources to arrive at a definitive diagnosis of lymphosarcoma. The use of

frozen sections can speed diagnosis, but these services are not widely available

to the veterinary practitioner. Occasionally, even the histologic or cytologic

differentiation of lymphoid malignancies from infectious or inflammatory disease

can be problematic. Because of the fractional kill phenomenon associated with

cancer chemotherapy, the turn-around time for conventional histopathology

results can be costly to the patient, particularly if the tumor has a short

doubling time. Without treatment, canine lymphosarcoma runs a rapid course and

is uniformly fatal, but the disease is responsive to various modes of

chemotherapy [10-12]. The clinician evaluates chemotherapeutic response by

symptomatology, radiology, and multiple clinical pathology parameters since no

test has been available that provides an index of surviving tumor cells. In

addition, the veterinary clinician has no specific test to predict impending or

frank relapse of the tumor; disease recurrence is normally detected when

lymphadenopathy recurs. At this point, tumor mass is again a detriment to

successful treatment. Our preliminary results indicate promising uses for p65 in

the initial diagnosis, post-therapy prognosis and routine follow-up examinations

to detect impending tumor relapse. The development of an p65 assay would provide

multiple benefits in the veterinary care of companion animals, and could be

available to practitioners. If future studies indicate that p65 is applicable

for use in other canine malignancies and/or in other companion animal species,

its potential value to the veterinary medical armamentarium would be

considerably amplified.

<PAGE>

         This study focused on the characterization, detection method

development, and clinical analysis of a unique 65-kD tumor-associated tumor

marker in canine cell line products and in stored plasma collected from canine

lymphosarcoma cases during the course of chemotherapy at University of Texas M.

D. Anderson Cancer Center (UTMDACC) Science Park Veterinary Resources

Department. The project's overall objective was the development of a

quantitative assay for the p65 tumor marker in the dog. In order to attain our

overall objective we completed p65 purification using high performance liquid

chromatography (HPLC) and polyacrylamide gel electrophoresis (PAGE) to obtain

purified p65. Purified p65 was used as standards in assays and as source

material in other project goals.

Materials and Methods

         Through a collaborative agreement with Dr. William C. Satterfield, an

Associate Professor of Veterinary Medicine and Surgery at our institution who

directs the Science Park Canine Lymphoma Referral Program, serum and plasma

samples were collected from over 80 plasma samples representing pre-treatment

and post-treatment time-points from 23 spontaneous canine lymphosarcoma cases

and control plasma and serum from 25 normal dogs.

         Purification of Canine p65

           The p65 is a labile phosphorylating protein whose purification has

been hampered by its lability and physical similarity with albumin. Absolute

HPLC purification remains difficult but we are confident that we can make

several improvements to our current HPLC protocol. We anticipate purchasing

additional HPLC columns to improve purification.

         Sample Preparation. Isolation starts with cell line material first

being fractionated with ammonium sulfate at 30-60% salt; the resulting pellets

<PAGE>

contain p65 and residual proteins. Alternatively, a barium chloride extraction

method is used on cruder samples, i.e. plasma, to eliminate all but 2% of plasma

proteins from the plasma. Pellets are stored in TMK or PBS buffer at pH 7.0-7.3

at -80(degree)C until analysis. For gels, a pellet is solubilized in

concentrated SDS sample buffer after dilution to appropriate protein levels

(30). For HPLC injection, pellets are dissolved in the equilibrating buffer,

filtered twice on 0.2u syringe units, and diluted.

         Chromatographic Separation. Prepared samples are injected onto a

molecular sieving column (GPC) for removal of extraneous proteins. Peak

fractions from this pass are pooled, concentrated, and stored with protease

inhibitors at -80(degree)C. When sufficient volumes of fractions are collected,

these samples are injected on hydrophobic interaction columns for a final

collection of the p65 peak.

         Electrophoretic Analysis. HPLC fractions are tested for p65 bands using

MW standards on multiple lane gels in both large and mini format on 12.5%

SDS-PAGE gels [31]. Typically, samples are run first on a Biorad minigel

apparatus at 90-100V for 90 minutes and stained with standard anionic dyes. Five

(5%) percent stacking gels are used to prefocus protein bands and improve

resolution. For optimal resolution and greater loading capacity, a large format

vertical apparatus is used (SE 600 Slab unit, Hoeffer Scientific, CA) to run

duplicate gels of the same loads. These 12.5% slab gels are cooled internally to

5(degree)C during runs of 500V for 2.5 hours. Gels are stained with Commassie

Blue R250 and de-stained in acetic acid, ethanol and distilled water.

Preparative electrophoresis kits for both units are used to load large

quantities of p65 to enable longer run times with cooling for greatest

resolution and highest possible p65 content (15 hrs, 25 milliamps). These gels

are then electroblotted (32) to nitrocellulose (Western blot). Polaroid film,

Kodak EDP paper, and dried preservation of the actual gel is used to record

stained bands.

         Avidin-biotin (Vectastain) Staining of Western Blots. For this

procedure blots were blocked in detergent buffer, probed with the p65 antibody,

<PAGE>

reacted with a biotinylated second antibody, and finally stained with a

colorimetric substrate to produce banding at p65 protein sites [33]. While only

qualitative data were produced, this assay is convenient for purposes of methods

development and for HPLC fraction testing.

         Protein A (labeled with 125I) detection of IgG on Western Blots. Blots

were probed with the polyclonal anti-p65 antibody and then stained with a

commercial Protein A reagent (ICN Biochemicals), which binds the 125I tag to the

IgG-bound sites on the blot [34]. Quantified data were collected and recorded on

AMBIS scans of the blot (AMBIS, Inc., San Diego, Ca.).

         Development of Monoclonal Antibodies

         Balb/c mice obtained from the National Cancer Institute, were immunized

with the purified human p65. Three to five animal were immunized at a time. The

animals were injected subcutaneously with 100 ug of the p65 marker emulsified as

a 1 : 1 mixture in complete Freund adjuvant. After 4-6 weeks, the animals were

injected intravenously with 10-100 ug of p65 for three consecutive days. On the

day following the third intravenous injection, the immunized mice were killed by

cervical dislocation, their spleen removed aseptically, and spleen cells were

prepared. The cells were then fused to the mouse myeloma cell line Sp0/2, which

was available from ATCC. Fusion of the mouse spleen cells with the mouse myeloma

cells was carried out as described in "Antibodies, A Laboratory Manual". The

supernatant of the growing hybrids was tested for the antibody that reacts with

the protein of MCF-7 cells by ELISA. Cell populations producing antibody to p65

were expanded by in vitro culture and subjected to cloning. The clones so

obtained were expanded, and supernatants from the monoclonal populations were

tested for the antibody by radioimmunoassay (RIA) or enzyme linked immunoassay

(ELISA).

         The antibodies were then screened for reactivity with the human

assay-marker (p65) as folllows. 100 ul of the hybridoma supernatant containing

<PAGE>

monoclonal marker with 300 ul of the culture medium from the 32P-labelled MCF-7

cells were incubated for 30 minutes. Next, 25 ul of affinity purified rabbit

anti-mouse immunoglobulin will be added. Following that procedure, the Staph.

aureus was added and the remainder of the screening technique was performed as

described in "Antibodies, A Laboratory Manual".

         Again, hybridoma supernatants containing monoclonal antibody that binds

the human p65 resulted in precipitation of this protein. Precipitation of the

protein wasbe visualized by gel electrophoresis and autoradiography.

         Partial Amino Acid Sequence of canine p65. We have conducted some

preliminary CNBr digestion experiments with canine p65. Six major peptides have

been obtained, and at least two of them were good candidates for amino acid

sequencing. It has been established that interspecies p65 sequences are closely

related since the CNBr digest patterns are identical in the case of the mouse,

rat, human and canine p65. The partial amino acid sequence of canine p65 was

determined as follows. The p65 from the lymphosarcoma cell line purified to

homogeneity [39] was derivatized and treated with CNBr as recommended by Applied

Biosystems (Foster City, CA). The resulting peptides were separated on

reverse-phase HPLC and subjected to automated Edman chemistry on an Applied

Biosystems model 477 pulsed liquid-phase sequencer equipped with an on-line

model 120A phenylthiohydantoin analyzer (Applied Biosystems), at the Department

of Molecular Pathology, UTMDACC-Houston. The partial amino acid sequence of

CNBr-cleaved fragments was matched with the p65 peptide fragment sequence

obtained from rat and human p65. Searches for amino acid homologies were done

using the GCG sequence analysis software available on-line via TEXNET at the

UTMDACC-Houston [40] and the protein sequence data base.

         Analysis of Data. Statistical analyses will be performed on a Macintosh

Plus computer, with Macintosh software for one-way analysis of variance and

<PAGE>

linear regression with P<0.05. Multiple comparison among groups will be

performed using the Neuman-Keuls procedure [51]. Student's t-test will also be

used. AMBIS scans from radiolabled blots and slab gels are stored on a computer

disk and accessed for data manipulation. Menu driven software allows formulation

of counts of binding reactions, etc., for downloading to spreadsheet programs

for statistical analysis.

Discussion

         In summary, although results are preliminary at this time, our findings

indicate that a diagnostic assay for p65 content in the dog appears valuable and

possible based on the following relevant points: (1) We have detected p65 in the

supernatant and nuclear fractions of several canine cell lines and in the plasma

of over 15 dogs with histologically confirmed lymphosarcoma, but not in

non-malignant control canine plasma samples [27-29]. Three systems have been

used to detect the p65 marker in dog plasma: the RNA transport-bioassay, and

Western blots of SDS-PAGE gels probed with specific antibody and detected with

either avidin-biotin or Protein A. Our data has shown that samples from dogs in

acute presenting or relapsing lymphosarcoma show consistent patterns of protein

overproduction in the 65-kD area. (2) We have demonstrated falling plasma p65

values after successful adriamycin therapy of histologically confirmed

lymphosarcoma in dogs and have shown that circulating p65 levels may have

predictive value in signaling an impending relapse. In cases of chemo-resistant

lymphosarcoma, we have demonstrated steady-state P65 levels indicative of

negligible reduction in tumor burden. (3) We have also demonstrated positive p65

staining in frozen sections and impression smears of excised canine

lymphosarcomatous, but not control, lymph nodes. Based on staining studies, the

marker has been identified to have potential application in cancer

immunohistochemistry (data not shown).

<PAGE>

REFERENCES

1.   McIntire,  K.R. 1984. Tumor Markers - How Useful are They? Hosp.  Practice,

     19:55-68.

2.   Cohn,  Susan L.,  Lincoln,  S.T., and Rosen,  S.T. 1986.  Present Status of

     Serum Tumor  Markers in  Diagnosis,  Prognosis  and  Evaluation of Therapy.

     Cancer Invest. 4:305-327.

3.   Bates,  Susan E. 1989. The Use and Potential of Serum Tumour  Markers,  New

     and Old. Drugs, 38(1):9-18.

4.   Haines, D.M. 1989. Immunohistochemical Detection of Osteosarcoma-Associated

     Antigen in Canine Osteosarcoma. Anticancer Res, 9(4):903-907.

5.   McEntee,  M., Isaacs, W., and Smith, C. 1987.  Adenocarcinoma of the Canine

     Prostate: Immunohistochemical Examination for Secretory Antigens. Prostate,

     11(2):163-170.

6.   Rosenthal,  R. C.  1982.  Epidemiology  of Canine  Lymphosarcoma.  Compend.

     Contin. Educ. Prac. Vet., 10:855-860.

7.   Theilen, G. H., and Madewell, B. R. 1979. Leukemia-Sarcoma Disease Complex,

     in Theilen G. H.,  Madewell,  B. R.  (eds.):  Veterinary  Cancer  Medicine,

     204-288.

8.   Dorn, C. R., Taylor, Don, and Schneider,  R., et al. 1968. Survey of Animal

     Neoplasms  in Alameda and Contra Costa  Counties,  California.  II.  Cancer

     Morbidity  in Dogs  and Cats  from  Alameda  County.  Natl.  Cancer  Inst.,

     40:307-318.

9.   Dorn, C. R., Taylor,  Don, and  Schneider,  R. 1970.  The  Epidemiology  of

     Canine Leukemia and Lymphoma. Bibl. Haemat., 36:403-415.

10.  Nancy, Postorino C., Susaneck, Steven J., Withrow, Stephen J., Macy, Dennis

     W., and Harris,  Cheryl.  1989.  Single Agent Therapy with  Adriamycin  for

     Canine Lymphosarcoma. J. of the Am. An. Hosp. Assoc., 25:221-225.

11.  Carter,  R.  F.,  Harris,  C. K.,  Withrow,  S. J.,  Valli,  V. E. O.,  and

     Susaneck,   S.   J.   1987.    Chemotherapy   of   Canine   Lymphoma   with

<PAGE>

     Histopathological  Correlation:  Doxorubicin Alone Compared to COP as First

     Treatment Regimen. Lymphoma Chemotherapy, 23:587-596.

12.  Ogilvie,  Gregory  K.,  Reynolds,  H. A.,  Richardson,  Ralph C.,  Withrow,

     Stephen J., Norris, A. M., Henderson, Ralph A., Klausner, J. S., Fowler, J.

     D., and  McCaw,  Dudley.  1989.  Phase II  Evaluation  of  Doxorubicin  for

     Treatment  of  Various  Canine   Neoplasms.   J.  Am.  Vet.  Med.   Assoc.,

     195(11):1580-1583.

13.  Drier,  J.K.,  Swanson,  P.E.,  Cherwitz,  D.L., and Wick,  M.R. 1987. S100

     Protein Immunoreactivity in Poorly Differentiated Carcinomas. Arch. Pathol.

     Lab. Med., 111:447-452.

14.  Safi, F., Bittner,  R., Roscher,  R., KUbel, R., and Beger,  H.G. 1987. The

     Value of CA 19-9 in  Gastric  and  Colorectal  Carcinoma.  Cancer  Invest.,

     5:401-407.

15.  Kelsten,  M.L., Chan, D. W., Bruzek,  D.J. and Rock, R.C. 1988.  Monitoring

     Hepatocelluloar  Carcinoma by Using a Monoclonal  Immunoenzymometric  Assay

     for Alpha-Fetoprotein. Clin. Chem., 34:76-81.

16.  Malogolowkin,  M.H., Ortega,  J.A., Krailo, M., Gonzalez,  O., Hossein, M.,

     Landing, B.H., and Siegel, S.E. 1989. Immature Teratomas: Identification of

     Patients at Risk for Malignant Recurrence. J. Natl. Can. Inst., 81:870-874.

17.  Stamey,  T.A., Yang, N., Hay, A.R., McNeal, J.E., Freiha, F.S. and Redwine,

     E. 1987.  Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of

     the Prostate. N. Engl. J. Med., 317:909-916.

18.  Lappohn,  Richard E., Burger, Henry G., Bouma, Joke, Bangah,  Mohan, Krans,

     Mindert,  and De Bruijn, Henk W. A. 1989. Inhibin as a Marker for Granulosa

     Cell Tumors. N. Eng. J. Med., 321:790-793.

19.  Lambert, Joanna. 1987. The Value of CA 125 Serum Assay in the Management of

     Ovarian Cancer. British Journal of Obstetrics and Gynaecology, 94:193-195.

20.  Shahangian,  Shahram,  Fritsche,  Herbert  A.,  Jr.,  Hughes,  John I., and

     Gelder,  Frank B.  1989.  Pancreatic  Oncofetal  Antigen  and  Carbohydrate

     Antigen 19-9 in Sera of Patients with Cancer of the Pancreas.  Clin. Chem.,

     35/3:405-408.

<PAGE>

21.  Schumm,  D.E.,  and  Webb,  T.E.  1982.  Putative  Transformation-Dependent

     Proteins in the Blood  Plasma of  Tumor-Bearing  Rats and Cancer  Patients.

     Cancer Res. 42:4964-4969.

22.  Hanausek-Walaszek,  M., Walaszek,  Z., and Webb, T.E. 1986. A 60 Kilodalton

     Oncofetal Protein as Tumor Marker. J. Med. 17:13-24.

23.  Hanausek-Walaszek,  M.,  Walaszek,  Z., Lang,  R.W.,  and Webb,  T.E. 1984.

     Characterization  of a 60,000 Dalton  Oncofetal  Protein from the Plasma of

     Tumor-Bearing Rats. Cancer Invest., 2:433-441.

24.  Schumm, D.E.,  Hanausek-Walaszek,  M.E., Walaszek, Z., and Webb, T.E. 1984.

     Absence of the  Cancer-Associated  Factor with a Molecular Weight of 60,000

     from the Plasma of Patients  with a Spectrum of  Nonneoplastic  Conditions.

     Cancer Res., 44:401-406.

25.  Walaszek, Z., Hanausek-Walaszek,  M., Schumm, D.E., and Webb, T.E. 1983. An

     Oncofetal   60-Kilodalton  Protein  in  the  Plasma  of  Tumor-Bearing  and

     Carcinogen-Treated Rats. Cancer Lett., 20:277-283.

26.  Hanausek-Walaszek,  M., Walazek,  Z., and Webb, T. E. 1985.  Carcinogens as

     Specific  Inducers  of a  60-Kilodalton  Protein  in Rats.  Carcinogenesis,

     6:1725-1730.

27.  Coghlan, L. G. and Hanausek,  M. Subcutaneous  Immunization of Rabbits with

     Nitrocellulose  Paper Strips  Impregnanted  with  Microgram  Quantities  of

     Protein. J. of Immunological Methods 129: 135-138, 1990.

28.  Hanausek-Walaszek,  M.,  Coghlan,  L. G., Rush,  J. J.,  Adams,  A. K., and

     Satterfield,  W. Studies of the 65kDa  Oncofetal RNA  Transport  Protein in

     Spontaneous Malignancies of Dogs. In preparation, to be submitted to Cancer

     Research.

29.  Hanausek, M., and Coghlan, L.G. 1988. Invention Disclosure Entitled "Method

     of  Monitoring  of Cancer  Treatment  in  Domestic  Animals,"  UTMDACC:136.

     Submitted to U.S. Patent Office on October 30, 1989.

30.  Bradford,  M. M. 1976. A Rapid and  Sensitive  Method for  Quantitation  of

     Microgram  Quantities of Protein  Utilizing  the  Principle of  Protein-Dye

     Binding. Anal. Biochem. 72:248.

<PAGE>

31.  Laemmli, U. K. 1970. Cleavage of Structural Proteins During the Assembly of

     the Head of Bacteriophage T4. Nature (London), 227:680-685.

32.  Towbin,  J.,  Staehelin,  T., and Gordon,  J.  Electrophoretic  Transfer of

     Proteins from Polyacrylamide Gels to Nitrocellulose  Sheets:  Procedure and

     Some Applications. 1979. J. Proc. Natl. Acid Sci. USA., 76:4350.

33.  Hsu, S. M., et al. 1981. Use of Avidin-Biotin  Peroxidase  Complex (ABC) in

     Immunoperoxidase  Techniques:  A Comparison of ABC and  Unlabeled  Antibody

     (PAP) Procedures. J. Histochem. Cytochem., 29:577-580.

34.  Fulton,  Scott P. 1989.  The Art of Antibody  Purfication.  Pub. 868, W. R.

     Grace and Co. Amicon Division.

35.  Bernstein,  Phillip  and Ross,  Jeffrey.  1989.  Poly(A),  Poly(A)  Binding

     Protein  and  the  Regulation  of mRNA  Stability.  Trends  in  Biochemical

     Sciences, 14(9):373-377.

36.  Case,  R., et al. A Single  Mutation  within CORE Element of Moloney Murine

     Leukemia Virus-TB Reduced Binding of a 42KD T-Lymphoma Cell Nuclear Factor.

     In press.

37.  Sachs,  Alan B., Davis,  Ronald W., and  Kornberg,  Roger D. 1987. A Single

     Domain of Yeast Poly(A)-Binding Protein is Necessary and Sufficient for RNA

     Binding and Cell Viability. Mol. Cell. Biol., 7(9):3268-3276.

38.  Conner,  J. D., and  Walpita,  P. 1989.  Identification  of Herpes  Simplex

     Viruses by Automated Profile Analysis of Viral Proteins.  J. Virol.  Meth.,

     24:245-252.

39.  Hanausek-Walaszek,  M., Del Rio, M., and Adams, A. K. 1990.  Structural and

     Immunological  Identity of P65 Tumor Associated  Factors from Rat and Mouse

     Hepatocarcinomas. Progress in Clinical and Biolog. Research, 331:105-120.

40.  Devereux,  I., Haeberli,  P., and Smithies, O. 1984. A Comprehensive Set of

     Sequence Analysis Programs for the VAX. Nucleic Acids Res., 12:387.

<PAGE>

41.  Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J., and Rutter, W. J. 1979.

     Isolation of Biologically  Active Ribonucleic Acid from Sources Enriched in

     Ribonuclease. Biochemistry, 18:5294.

42.  Gubler,  U.,  and  Hoffman,  B. J. A Simple and Very  Efficient  Method for

     Generating cDNA Libraries. 1983. Gene, 25:263.

43.  Young, R. A., and Davies, R. W. 1983. Efficient Isolation of Genes by Using

     Antibody Probes. Proc. Natl. Acad. Sci. U.S.A., 80:1194.

44.  Young,  R. A., and  Davies,  R. W.  1983.  Yeast RNA  Polymerase  II Genes:

     Isolation with Antibody Probes. Science, 222:778.

45.  Coloma, J., and Pitot, H. C.  Characterization and Sequence of a cDNA Clone

     of Gamma-Glutamyltranspeptidase. 1986. Nucleic Acids Res., 14:1393.

46.  Maniatis,  T., Fritsch, E. F., and Sambrook, J. 1982. J. Molecular Cloning:

     A Laboratory Manual. Cold Spring Harbor, N.Y., 1982.

47.  Weinberg, C., Hollenberg, F. M., Ong, E. F., Harmon, J. M., Browner, S. M.,

     Sidlowsky,  J., Thompson,  E. B., Rosenfeld,  M. G., and Evans, R. M. 1985.

     228:740.

48.  Messing,  J. 1983.  New M13  Vectors  for  Cloning.  Methods  in  Enzymol.,

     101:20-78.

49.  Hennikoff, S. 1987. in: Promega Notes. Promega Corp. Madison, WI.

50.  Sanger,  F.,  Nicklen,  S., and Coulson,  A. R. 1977. DNA  Sequencing  with

     Chain-Terminating Inhibitors Proc. Natl. Acad. Sci. U.S.A., 74:5463

51.  Armitage,  P. 1971.  Statistical Methods in Medical Research.  J. Wiley and

     Sons, New York, p. 205.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00081-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00081-of-00352.parquet"}]]